



Mouse Anti-Denosumab monoclonal antibody, clone 0B21 (CABT-ZB197)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	CABT-ZB197 is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Denosumab.
Specificity	The product is specific for Denosumab.
Target	Denosumab
Immunogen	Denosumab
Isotype	IgG1, κ
Source/Host	Mouse
Clone	0B21
Purification	Protein A purified
Conjugate	Unconjugated
Applications	ELISA(det), PK study Recommended Working Concentration: 0.001-0.05 µg/ml We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB196 - CABT-ZB197
Reconstitution	Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Format	Purified, Lyophilized.
Size	40 µg

Buffer	Lyophilized with PBS, pH 7.2, contains 0.02% sodium azide.
Preservative	0.02% sodium azide
Storage	The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles.
Ship	Wet ice

BACKGROUND

Introduction	Denosumab with trade name Prolia, is an FDA-approved drug for the treatment of patients with osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. Denosumab is a fully human monoclonal antibody that works as a RANK ligand (RANKL) inhibitor. Denosumab can bind RANKL, preventing RANKL from activating RANK, its receptor on the osteoclast surface.
Keywords	Mouse monoclonal antibody to Denosumab/Prolia; AMG 162; Denosumab

GENE INFORMATION

Synonyms	Mouse monoclonal antibody to Denosumab/Prolia; AMG 162; Denosumab
-----------------	---